RNA binding protein RBM5 modulates chemotherapy resistance

• Project/Area Number: 22590677
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Hokkaido University
• Principal Investigator: KOBAYASHI Takahiko 北海道大学, 大学院・医学研究科, 客員研究員 (80333607)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
• Keywords: 薬剤耐性 / 抗癌剤 / RBM5 / 抗癌剤耐性

Research Abstract

Prognostic value of RBM5 in gastric cancer was evaluated and compared with other histopathologic parameters. RBM5 protein expression was determined by immunohistochemistryin 106 gastric carcinomas. Reduced expression of RBM5 was observed in 29 cases (27.4%), and it was correlated with tumor size, depth, histological classification, and advanced stage. Furthermore, it was significantly associated with unfavourable prognosis. Furthermore, knockdown of endogenous RBM5 led to decreased p53 and p21 protein expression levels in gastric cancer cells, and increased drug resistance against 5-fluorouracil. Taken together, these results suggest that decreased function of RBM5is associated with malignant transformation and resistance to cancer chemotherapies.

Research Products

• [Journal Article] p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. (2011)
  • Author(s): Kobayashi T, Ishida J, Musashi M, Ota S, Y oshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayas hi M, Itoh H, Edamatsu H, Sutherland LC, B rachmann RK.
  • Journal Title: Int J Cancer Volume: 128(2) Issue: 2 Pages: 304-318
  • DOI: 10.1002/ijc.25345
  • Peer Reviewed
• [Journal Article] Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin (2011)
  • Author(s): Asanuma S., et.al.
  • Journal Title: Ann Hematol Volume: 90 Issue: 6 Pages: 617-624
  • DOI: 10.1007/s00277-010-1121-z
  • Peer Reviewed
• [Journal Article] p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. (2011)
  • Author(s): Kobayashi T
  • Journal Title: Int J Cancer Volume: 128 Pages: 304-318
  • Peer Reviewed